SDX 102

Drug Profile

SDX 102

Alternative Names: Alanosine; L-alanosine; NSC-153353

Latest Information Update: 25 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); University of California, San Diego
  • Developer Salmedix
  • Class Cytostatic antibiotics
  • Mechanism of Action Adenylosuccinate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain cancer; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma

Most Recent Events

  • 16 Jun 2005 Salmedix has been acquired by Cephalon
  • 04 May 2005 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV)
  • 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top